Get the Stockscreener App
213.02
1.36%
3.62
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $213.02, with a volume of 1.26M.
It is up +1.36% in the last 24 hours and down -8.55% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$209.40
Open:
$212.26
24h Volume:
1.26M
Relative Volume:
0.19
Market Cap:
$376.75B
Revenue:
$61.16B
Net Income/Loss:
$4.19B
P/E Ratio:
90.21
EPS:
2.3614
Net Cash Flow:
$17.82B
1W Performance:
+3.57%
1M Performance:
-8.55%
6M Performance:
-8.33%
1Y Performance:
+3.39%
1-Day Range:
$210.78
$213.25
1-Week Range:
$201.80
$213.49
52-Week Range:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
213.00 | 370.38B | 61.16B | 4.19B | 17.82B | 2.3614 |
LLY
Lilly Eli Co
|
890.91 | 784.58B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
241.75 | 579.15B | 94.19B | 26.80B | 19.70B | 11.05 |
AZN
Astrazeneca Plc
|
194.38 | 292.21B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
119.25 | 295.77B | 64.93B | 18.26B | 12.36B | 7.2751 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
-0.83% for AbbVie stock as shares remain under key resistance levels - Traders Union
-0.83% for AbbVie stock as price remains below key moving averages - Traders Union
This Top ETF Recently Added a Healthy Dose of These High-Yielding Dividend Stocks - The Motley Fool
Taxes of AbbVie, Inc. – BSESOF:4AB - TradingView
AbbVie, Inc. Trade Ideas — BSESOF:4AB - TradingView
Wedge Capital Management L L P NC Sells 6,019 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Stock Holdings Lifted by Waycross Partners LLC - MarketBeat
Is AbbVie Inc. (ABBV) one of the debt free halal stocks to buy? - MSN
Bell Bank Has $12.09 Million Stake in AbbVie Inc. $ABBV - MarketBeat
AbbVie Dermatology Data Sparks Questions On Growth Potential And Valuation - Yahoo Finance Singapore
Wealthcare Advisory Partners LLC Grows Stake in AbbVie Inc. $ABBV - MarketBeat
Generate Investment Management Ltd Sells 49,224 Shares of AbbVie Inc. $ABBV - MarketBeat
TABR Capital Management LLC Takes Position in AbbVie Inc. $ABBV - MarketBeat
Exchange Traded Concepts LLC Increases Stock Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Bought by Capital Investment Advisors LLC - MarketBeat
AbbVie stock slips 0.83% as company highlights commitment to raising care standards at congress - Traders Union
Return on equity % of AbbVie, Inc. – BSESOF:4AB - TradingView
AbbVie: Strong 2026 Outlook, Expect Dividend Increases (NYSE:ABBV) - Seeking Alpha
AbbVie’s Global IBD Outcomes Study: What Treat-to-Target Data Could Mean for Investors - tipranks.com
AbbVie stock price forecast: bearish momentum persists as ABBV trades below major moving averages - Traders Union
AbbVie stock edges down after AAD2026 event highlights commitment to dermatology standards - Traders Union
AbbVie touts 5-year arthritis data and late-breaker vitiligo results - Stock Titan
World Investment Advisors Increases Position in AbbVie Inc. $ABBV - MarketBeat
Global X Japan Co. Ltd. Increases Stock Position in AbbVie Inc. $ABBV - MarketBeat
Synergy Asset Management LLC Sells 10,070 Shares of AbbVie Inc. $ABBV - MarketBeat
Here's How Many Shares of AbbVie (ABBV) Stock You'd Need for $10,000 in Yearly Dividends - The Globe and Mail
Dakota Wealth Management Raises Position in AbbVie Inc. $ABBV - MarketBeat
Integras Partners LLC's AbbVie Inc(ABBV) Holding History - gurufocus.com
AbbVie (NYSE:ABBV) Trading 1.9% HigherTime to Buy? - MarketBeat
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
Vanguard disaggregates holdings after internal realignment (ABBV) - Stock Titan
AbbVie stock price forecast: sustained weak momentum as ABBV recovers modestly to $207.15 - Traders Union
Moody National Bank Trust Division Sells 5,674 Shares of AbbVie Inc. $ABBV - MarketBeat
AQR CVX Fusion Fund's AbbVie Inc(ABBV) Holding History - GuruFocus
Czech National Bank Purchases 17,373 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie, Novartis Sue Wash. Over New 340B Drug-Pricing Law - Law360
How AbbVie’s official partnership with MLB will unfold over the course of the season - Medical Marketing and Media
AbbVie (NYSE:ABBV) Expands Awareness And Psychedelic Research Russell 1000 - Kalkine Media
Market Outlook: Can AbbVie Inc stock double in the next yearTrend Reversal & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Investors heavily search AbbVie Inc. (ABBV): Here is what you need to know - MSN
AbbVie Inc stock faces renewed scrutiny as Mercy Investment files shareholder proposal amid pipeline - AD HOC NEWS
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know - Yahoo Finance
LLY or ABBV: Which Drugmaker is Likely to Offer Better Upside in 2026? - TradingView
AbbVie stock price forecast for 2040: Immunology pipeline and oncology expansion support long-term path toward $550 - tradersunion.com
Pensionfund Sabic Invests $4.02 Million in AbbVie Inc. $ABBV - MarketBeat
Meadowbrook Wealth Management LLC Grows Stake in AbbVie Inc. $ABBV - MarketBeat
DAVENPORT & Co LLC Sells 5,545 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV is Bill Few Associates Inc.'s 7th Largest Position - MarketBeat
Is AbbVie (ABBV) one of the Best Psychedelic Stocks to Buy in 2026? - Insider Monkey
AbbVie Inc stock faces activist pressure as Mercy Investment files shareholder proposal amid pipelin - AD HOC NEWS
AbbVie’s sports marketing move - emarketer.com
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):